Nature Reviews Drug Discovery

Papers
(The median citation count of Nature Reviews Drug Discovery is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)
ArticleCitations
New target for anorexia2772
Alzheimer antibody rush begins, as efficacy concerns remain1484
Will psychedelics be ‘a revolution in psychiatry’?1479
Mechanism mediating methylenomycin production1082
Generating neurons in the adult brain932
First clinical test of an in vivo CRISPR candidate shows deep protein knockout potential868
Upcoming market catalysts in Q3 2021805
New CAR’s bells and whistles795
Brain glucose mediates amphotericin B tolerance659
Acyl-lysine reader inhibitor blocks AML progression600
Identifying selective PI3KC2α inhibitors587
Putting a PIN in pancreatic cancer569
A cancer drug wish list532
FDA approves first-in-class NK3 receptor antagonist for hot flushes463
Hypoimmune iPSCs escape immune detection440
Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?408
A spirulina-based biomanufacturing platform401
Small-molecule screens for targeting non-coding RNA392
Vertex’s NaV1.8 inhibitor passes phase II pain point376
Monoclonal antibody treats yellow fever370
DENV inhibitor effective in non-human primates356
Decrypting drug action at the level of PTMs355
PKN3: a target in cancer metastasis330
A new path to targeted protein degradation?316
FDA approval of Immunocore’s first-in-class TCR therapeutic broadens depth of the T cell engager platform312
Pandemic vaccines: a formidable challenge for pharmacovigilance310
Neurons give metastatic cells a push304
Apolipoprotein L2 inhibitor mitigates fibrosis289
RAS-targeted therapies287
Non-antibiotic drug network reveals new leads for antibiotics287
Kinase inhibitor rescues the liver281
AI serves up target and inhibitor for lung fibrosis280
FDA approves first complement factor D inhibitor277
Synthesizing portimines275
A ROS-mediated resistance pathway to anticancer drugs271
The importance of persistence in cancer drug development266
Novo Nordisk and GlaxoSmithKline buy into RNAi262
FDA approves first Friedreich’s ataxia drug254
Overcoming ICB resistance in lung cancer252
Allosteric adenosine receptor modulator alleviates pain242
Rediscovering hygromycin A for Lyme disease treatment232
Towards polio eradication217
Massive misuse of chemical probes undermines the utility of these tools198
Treating cannabis use disorder196
What’s next for an immuno-oncology powerhouse?194
Stalled molecular motor inhibits tumour growth193
Shifts in the clinical trial landscape191
The pipeline and market for migraine drugs189
The KRAS crowd targets its next cancer mutations182
Nanoparticle chirality sets the dial on immunogenicity181
mRNA-encoded monoclonal antibody fights CHIKV162
BRAF plus MEK inhibitor combo secures tumour-agnostic FDA approval158
FDA new drug approvals in Q1 2023154
Eli Lilly spends $3.2 billion on Morphic’s oral integrin inhibitor for inflammatory bowel disease152
Epigenetic editor silences prion protein151
Comprehensive measurement of biopharmaceutical R&D investment151
New naming scheme for antibodies drops the -mab stem150
Comparing development strategies for PD1/PDL1-based immunotherapies147
Understanding the effects of antibiotic combinations143
Top companies and drugs by sales in 2020126
Therapeutic RNA-silencing oligonucleotides in metabolic diseases125
Targeting tumour N-glycosylation123
GlaxoSmithKline buys late-stage JAK inhibitor for $1.9 billion122
Ipsen buys Epizyme for US$247 million116
Promoting tissue repair after heart attack114
Weeding out toxic RNA in Huntington disease113
Pasting in large DNA sequences112
Understanding long-lasting ketamine effects108
Targeting tumour-associated bacteria104
Bacteria tag tumours for CAR-T cell attack103
FDA new drug approvals in Q1 202199
First-in-class IL-15 receptor agonist nabs FDA approval for bladder cancer98
The improving benefit–risk balance of phase I cancer trials94
A specific biomarker for insoluble tau89
Vaccine exposes tumours to immune cell attack87
Improving circular RNA protein yields87
Pfizer buys Biohaven’s migraine drugs for $11.6 billion81
Neutralizing Zika virus80
Upcoming market catalysts in Q1 202380
Upcoming market catalysts in Q3 202280
mRNA vaccines for infectious diseases — advances, challenges and opportunities79
A viral–lipid hybrid delivery system for genetic therapies78
Pull incentives for antibiotics get push from the UK73
FDA approves first hypoxia-inducible factor prolyl hydroxylase inhibitor73
Novartis’s canakinumab stumbles in cancer, again72
Open-science drug discovery for COVID-1969
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors68
Gene therapy zeroes in on Parkinson disease brain circuits68
Ribosome-targeted antibiotic tackles antimicrobial resistance68
MYC inhibitor achieves phase I success67
Orphan drug designation and development in Japan: 25 years of experience and assessment67
A novel approach to boost drug development in paediatric oncology66
Lipid metabolite triggers neural repair64
Targeting EMT in cancer through netrin-162
Trustworthy AI for safe medicines61
Impact of regulatory system changes on the availability of innovative drugs in China60
Lilly’s tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics58
Towards a broad-spectrum flavivirus vaccine58
Anti-oncostatin M antibody puts brakes on asthma exacerbations57
Targeting drug-resistant glioblastoma55
The landscape and market for HIV therapies54
Trust in Science: a novel research partnership model in Latin America53
mRNA flu shots move into trials52
FDA approves first all-oral sleeping sickness drug52
Chemical engineering of CRISPR–Cas systems for therapeutic application51
Engineering the next generation of cell-based therapeutics50
Targeting aggressive AML48
Function and therapeutic value of astrocytes in neurological diseases48
LRRK2 inhibitor progresses for Parkinson disease47
ASO to treat Timothy syndrome47
eTRANSAFE: data science to empower translational safety assessment46
Bispecific antibodies in oncology46
Clinical trial strategies for rare neurodevelopmental disorders: challenges and opportunities45
Disease interception at scale: how a five-million-person study plans to transform healthcare45
Top companies and drugs by sales in 202144
FDA approves first-in-class AKT inhibitor43
Splice-switching ASO curtails brain calcification43
Creating an AI-first drug discovery engine42
Protein isoform-centric therapeutics: expanding targets and increasing specificity41
Degrading cell-free DNA to prevent recurrent stroke40
RNA-rewriting candidate moves into the clinic39
FDA outlines steps for individualized drug development39
The R&D landscape for infectious disease vaccines39
Evolution of innovative drug R&D in China39
Suppressing tumour Treg cells with a histone demethylase inhibitor38
Therapeutic targeting of the functionally elusive TAM receptor family38
The glymphatic system: implications for drugs for central nervous system diseases36
Emerging concepts in the science of vaccine adjuvants35
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment34
Double setback for ASO trials in Huntington disease32
Therapeutic strategies for COVID-19: progress and lessons learned32
2022 FDA approvals32
FDA approves second RNA aptamer31
FDA approves first GPRC5D × CD3-targeted bispecific for multiple myeloma30
Unrealized targets in the discovery of antibiotics for Gram-negative bacterial infections29
Targeted protein degraders crowd into the clinic29
NASH field celebrates ‘hurrah moment’ with a first FDA drug approval for the liver disease29
opnMe.com: a digital initiative for sharing tools with the biomedical research community29
PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx28
Muscarinic drugs breathe new life into schizophrenia pipeline27
Advanced technologies for the development of infectious disease vaccines26
Anti-tau antibody stumbles in phase II Alzheimer trial26
Author Correction: Disease modification in inflammatory skin disorders: opportunities and challenges26
Accelerating antiviral drug discovery: lessons from COVID-1925
Glucose-sensitive insulin protects against hypoglycaemia25
Antiviral target compound profile for pandemic preparedness25
Targeting neurofibrosis reverses metabolic dysfunction24
Tumour cells get a dendritic cell makeover24
FDA approves first schizophrenia drug with new mechanism of action since 1950s24
Antibody vanquishes SARS-CoV-2 variants24
Error-corrected next-generation sequencing to advance nonclinical genotoxicity and carcinogenicity testing24
Trends in kinase drug discovery: targets, indications and inhibitor design23
Author Correction: Bridging the gap between innovation and later-stage financing for biotech in Europe23
Amplifying gene expression with RNA-targeted therapeutics22
Thinking outside the box: non-canonical targets in multiple sclerosis22
The evolving role of investigative toxicology in the pharmaceutical industry20
Targeting HER2-positive breast cancer: advances and future directions19
FDA approves 100th monoclonal antibody product19
Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation19
Delivering on the promise of protein degraders19
Targeting inflammation in atherosclerosis — from experimental insights to the clinic19
Small-molecule discovery through DNA-encoded libraries18
Drugging the NLRP3 inflammasome: from signalling mechanisms to therapeutic targets17
FDA approves first biparatopic antibody therapy17
FDA approves second TTR stabilizer for cardiac amyloidosis17
DUBTACs for targeted protein stabilization17
Author Correction: B cell depletion therapies in autoimmune disease: advances and mechanistic insights17
Circular RNA vaccines expose cryptic peptides16
Clipping cell-surface mucins in cancer by targeted degradation16
FDA approves second BCMA-targeted CAR-T cell therapy16
FDA approves new antibiotic combination for drug-resistant pneumonia16
Tripeptide treats NASH in non-human primates15
Screening ultra-large virtual libraries15
Antibody offers broad alphavirus protection15
A new antibiotic for A. baumannii14
Upcoming market catalysts in Q3 202314
Hooking FSH as a potential target for Alzheimer disease14
FDA releases tissue-agnostic cancer drug draft guidance13
Understanding sphingosine-1-phosphate transport13
A closer look at molecular glues13
A type 1 regulatory T cell-based therapy13
Reflections on 10 years of the FDA’s breakthrough therapy designation12
What’s next for the synthetic lethality drug discovery engine?12
Repurposing sapanisertib in malaria12
IMI European Lead Factory — democratizing access to high-throughput screening12
Trends in the global antibiotics market12
Identifying degrader hotspots12
T cell-regulating therapies for autoimmune diseases take FDA rejection in stride12
Drug targeting in psychiatric disorders — how to overcome the loss in translation?12
Pfizer’s COVID-19 vaccine secures first full FDA approval11
Preclinical cancer research suffers another reproducibility blow11
From pandemic preparedness to public–private partnerships11
Phosphatase inhibitor drives anticancer immune responses11
Restoring memory in aged mice11
CRISPR technologies are going to need a bigger toolbox11
Molecular glue-like STING activator11
Plant protein blocks tumour growth11
Host-directed antiviral blocks SARS-CoV-2 entry10
NUAK1 inhibition prevents fibrosis10
Antibody cocktail eliminates ebolaviruses10
FDA authorizes first single-shot COVID-19 vaccine10
Rewired proteostasis in KRAS inhibitor resistance10
Translational misconceptions10
Stress can be exhausting for T cells10
MDMA-assisted therapy for PTSD passes phase III trial10
Macrocyclic peptides thwart Gram-negative bacteria10
The significance of blockbusters in the pharmaceutical industry10
Trends in drug development for amyotrophic lateral sclerosis9
Targeting ROS in cancer: rationale and strategies9
Virtual screening yields refined GPCR agonists9
Antisense technology: an overview and prospectus9
Setting GPCRs free9
Enhancing in situ cancer vaccines using delivery technologies9
PI3K inhibitors are finally coming of age8
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders8
The emerging role of mass spectrometry-based proteomics in drug discovery8
Upcoming FDA approval decisions in Q1 20258
Towards a universal flu vaccine8
Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape8
VEGFA mRNA for regenerative treatment of heart failure8
Emerging therapeutic opportunities for integrin inhibitors8
Targeting lipid–protein interaction in AML8
Understanding NMDA-mediated ketamine activity8
Zebrafish disease models in drug discovery: from preclinical modelling to clinical trials8
Lipogenesis inhibitors: therapeutic opportunities and challenges8
Membrane transporters in drug development and as determinants of precision medicine8
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap8
Loss of Y chromosome promotes cardiac fibrosis8
NK2R agonist delivers one-two punch to obesity8
Pan-serotype antiviral for dengue infection7
Muscarinic receptor modulators for schizophrenia attract multibillion-dollar attention7
Understanding PI3K inhibitor mechanism of action7
Bispecific antibodies pin down cancer stem cells7
Can a platform of platform companies open up more opportunities?7
Inhibiting cap snatching7
Blocking breast cancer metastasis7
Nonhormonal target for endometriosis7
Plasmacytoid dendritic cell depletion treats lupus7
Predicting Alzheimer disease dementia7
Upcoming market catalysts in Q4 20217
Towards a pan-serotype dengue antiviral7
R&D re-balancing act7
Reactivating PTEN promotes antitumour immunity7
2021 FDA approvals: value driven by COVID-19 vaccines6
FDA approves first DLL3 × CD3 bispecific T-cell engager for lung cancer6
Healing wounds without scarring6
Combating antimicrobial resistance in malaria, HIV and tuberculosis6
Development of Chinese innovative drugs in the USA6
Lysosomal channel regulates PD pathology6
The pipeline and market for psoriasis drugs6
0.14834713935852